Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Visx

This article was originally published in The Gray Sheet

Executive Summary

Company President Elizabeth Davila named CEO, effective Feb. 13. Outgoing CEO Mark Logan will remain board chairman until firm's next annual meeting. Separately, Federal Trade Commission drops suit against Visx following Patent and Trademark Office's issuance of a reexamination certificate for Visx's '388 patent. FTC had appealed a June 1999 FTC administrative law judge dismissal of the patent fraud complaint (1"The Gray Sheet" June 28, 1999, In Brief)

You may also be interested in...



Visx

Federal Trade Commission files notice of appeal of an FTC administrative law judge's June 4 decision to dismiss an FTC complaint of alleged patent fraud. The commission is expected to review the case and issue a final decision in about a year. Visx, noting that "the FTC almost always appeals adverse administrative rulings to the full commission," says it will appeal any adverse commission decision to a federal court of appeals

Interview: Spain's Sanifit Set For Significant 2020

The Mallorca-based biotech is building a strong data package for SNF472 which the company believes will be an effective treatment for a number of calcification disorders in dialysis patients.

Sun Denied Over US Antitrust Challenge

India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.

UsernamePublicRestriction

Register

MT014512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel